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Introduction
Research into the possibility of developing a vaccine 
against influenza began soon after the virus was isolated 
in 1933 [1]. In the following years, a great deal of work 
was carried out in order to achieve this objective, and in 
1945 the first licence to produce a vaccine for civilian use 
was granted in the United States (U.S.), as described in 
the reviews by Francis and by Wood and Williams [2, 3].
This vaccine, which was prepared in anticipation of the 
1945-46 influenza season, contained two viral strains: 
one type A (A/PR8/34) and one type B (B/Lee/40). 
These strains were cultivated on embryonated chicken 
eggs in accordance with the technique of Burnett [4], in-
activated with formol, and purified and concentrated by 
means of erythrocyte adsorption/elution [5]. Erythrocyte 
agglutination testing was utilised in order to measure 
the quantity of antigen present in a dose, while immu-
nogenicity was evaluated by means of the agglutination 
inhibition test [6]. The vaccine was authorised chiefly 
on the basis of a series of controlled clinical studies con-
ducted by the U.S. Armed Forces, which documented its 
safety and effectiveness.
The interest of the U.S. military in developing an influ-
enza vaccine stemmed from the experience of the 1918 
influenza pandemic. Having broken out in North Caro-
lina in March 1918, the pandemic swept through the 
troops of the American Expeditionary Force, who had 
been sent to support the Western allies in April of that 
year. The effect was devastating both for the soldiers 
and for the civilian populations to whom the virus was 
transmitted. For this reason, since 1946 the entire U.S. 
Army has been vaccinated against influenza.
The virus B epidemic of the winter of 1945-46 (the first 
year that the vaccine was used) provided further evi-
dence of the efficacy of the vaccine [7]. However, in the 
winter of 1946-47, the new vaccine ran up against an 
obstacle: antigenic drift. Indeed, an antigenic variant of 
the strain A, named A/FM1/47, appeared in Australia 
and rapidly spread worldwide, reducing the protective 
efficacy of the vaccine to very low values [8-10]. This 
event not only prompted the U.S. Commission on In-
fluenza to incorporate the new strain into the vaccine 
for the 1947-48 winter season, instead of the previous 
strain A/PR8/34, but also brought to light the problem 
of appropriate selection of the viral strains to be used in 
vaccines.
Selection of vaccine strains
Convincing evidence of the need to carefully select the 
strains for insertion into the influenza vaccine prompted 
the World Health Organization (WHO) in April 1957 
to constitute a small committee to study the vaccine. It 
was established that the World Influenza Centre should 
coordinate the work of laboratories and spread appro-
priate information. The first centre to be set up was in 
London, followed, a few years later, by that of Bethesda. 
The centres worked together to establish a worldwide 
viral surveillance network, and by 1953, 54 centres in 42 
countries were able to provide information on circulat-
ing viruses.
In the same year, the WHO also began informing govern-
ments as to the correct choice of vaccine strains. Recom-
mendations regarding the northern hemisphere are still 
issued in the middle of February, while for more than 
10 years, recommendations for the southern hemisphere 
have been issued in the middle of September. The strains 
recommended by the WHO are selected on the basis of 
their antigenic and genetic features.
Improvement in vaccine production
Antigenic drift was not the only obstacle to the diffusion 
of influenza vaccination. A very delicate step was that of 
the concentration/purification of the viral suspensions in 
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the first place. The erythrocyte adsorption/elusion tech-
nique did not allow large amounts of vaccine to be pro-
duced, while the other methods did not yield satisfactory 
results in terms of tolerability.
The introduction of the Sharple centrifuge for the clarifi-
cation of the allantoid fluid, saccharose-gradient centrif-
ugation and the availability of continuous-flow zonal cen-
trifuges at the industrial level enabled highly purified and 
concentrated viral suspensions to be prepared [11-14].
Whole-virus vaccines proved to be well tolerated by 
adults and the elderly, but less so by children and young 
people. For this reason, attention was again turned to the 
research by Davenport et al. [15], which had shown that 
vaccines prepared with influenza virions split by means 
of ether and Tween80 caused fewer febrile reactions than 
whole-virus vaccines, while maintaining good immunis-
ing properties. This gave rise to the production of “split 
vaccines”, which were authorised in the United States in 
1968 and subsequently throughout the world. New split-
ting techniques were also developed and utilised by vac-
cine producers in various countries [16-18].
Numerous controlled clinical studies demonstrated that 
fragmentation of the virions did not impair the immuno-
genicity of the vaccine, while it did reduce reactogenici-
ty, especially in young subjects. These studies, however, 
also revealed that the split vaccines were not as immuno-
genic as whole-virus vaccines in unprimed subjects.
A further step forward was the production of vaccines 
containing only viral haemagglutinin and neuraminidase 
and minimal traces of internal proteins [19-23]. These 
vaccines are well tolerated both by young children and 
by subjects who are sensitive to exogenous antigens, 
such as asthmatics. Nevertheless, like split vaccines, 
they are less immunogenic than whole-virus vaccines.
Another important practical advance was the develop-
ment of a method of obtaining re-assortant viral strains 
with a high capacity to grow in embryonated chicken 
eggs [24]. This enabled larger amounts of vaccine to be 
produced in a shorter time, even though recently iso-
lated viral strains have displayed scant ability to grow 
in eggs.
Improvement of vaccine standardization 
and quality control
The evolution of the methods of vaccine preparation 
also necessitated the development of new techniques 
for evaluating the potency of vaccines. Initially, potency 
was measured in Chicken Cell Agglutination (CCA) 
units, according to the erythrocyte agglutinating titre. 
This technique was further refined through the establish-
ment by the WHO of an International Standard, which 
enabled the potency of a vaccine to be expressed in In-
ternational Units.
The development of split vaccines and subunit vaccines, 
however, raised the need to work out a new method of 
comparative evaluation of the antigenic content of the 
various influenza vaccines. To this end, the radial single 
immunodiffusion test [25] was adopted, which enables 
the antigenic content of a vaccine to be expressed in mi-
crograms of haemagglutinin. In Europe, the potency of 
inactivated vaccines for use in annual influenza preven-
tion campaigns is currently measured also by determin-
ing the appearance or increase of agglutination-inhibit-
ing antibodies following administration of the vaccine to 
volunteers in clinical trials.
Methods of assessing vaccine purity have also been 
steadily updated, and limits have been placed on the lev-
els of ovalbumin and endotoxins.
Adjuvants
The idea of potentiating the immunogenicity of influ-
enza vaccines through the addition of adjuvants can be 
traced back throughout the entire history of inactivated 
influenza vaccines. This need became particularly evi-
dent when controlled clinical studies clearly showed that 
the classical split vaccines were less efficacious not only 
in young children, but also, owing to a physiological 
mechanism of “immunosenescence”, in subjects aged 
over 65 years, who account for a large portion of the 
population requiring priority protection. 
In addition, since the early 2000s, the increasing expec-
tation of a severe pandemic caused by a virus of avian 
origin has intensified research into adjuvants. The main 
advantages yielded by an appropriate adjuvant are:
antigen saving (i); enhanced immunogenicity of the 
vaccine in hyporesponsive subjects (ii); “broadened” 
immune responses, with protection also against drifted 
viral strains that are not present in the vaccine (probable 
cross-protection) (iii).
The key issue, which needs to be examined with great 
care and attention, is that of safety, in both the short and 
long term, in groups of individuals with different char-
acteristics. The substances used and the experimental 
procedures adopted in order to achieve these objectives 
are too numerous to be listed here. 
The first countries to authorise the use of adjuvated vac-
cines were in Europe; only recently they were licensed 
in the U.S. In Italy, the first adjuvants to be incorpo-
rated into the vaccines prepared for seasonal influenza 
prevention campaigns were MF59 and virosomes. The 
first controlled clinical trial involving MF59 was under-
taken in 1992-93 by Chiron Vaccine (today Novartis) in 
collaboration with our institute, and was prolonged for 
three consecutive seasons [26]. Since then, several mil-
lion elderly subjects have received doses of the vaccine, 
especially during the seasonal prevention campaigns; 
the results have been very satisfactory in terms of im-
munogenicity, tolerability and safety [27].
MF59 has been thoroughly investigated as an adjuvant 
to vaccines prepared against avian influenza, and has 
proved able both to potentiate immunogenicity and to in-
duce cross-protection against moderately drifted strains 
of the virus A/H5N1. Finally, MF59 was used as an ad-
juvant in the vaccine (Focetria®) against the 2009-2010 
pandemic caused by a virus of swine origin, the proto-
type of which is the strain A/California09/H1N1 [28].
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The virosomal vaccine is a particular form of liposomal 
vaccine in which the surface glycoproteins of the virus 
are attached to both surfaces of the liposome [29]. A re-
cent review by Gasparini et al. documents the very good 
tolerability and good immunogenicity of virosomal vac-
cines in various age-groups [30].
Other recent developments include:
•  the availability of a vaccine made up of live attenuat-
ed viruses for intranasal administration (LAIV); this 
vaccine was authorised in the U.S. in 2003, and in 
Italy and Europe for the 2011-2012 season [31, 32];
• the availability, since the 2010-2011 season, of an in-
activated vaccine for intradermal administration. The 
immunising dose, which is concentrated in a volume 
of 0.1ml, comes in a syringe-container which ensures 
release of the vaccine at the level of the dermis [33];
• the “reverse transcriptase” method of handling viral 
strains to be used as seeds for vaccine production. 
This is more complex than re-assortment, but re-
quires less time to produce the seed virus [34, 35];
• the production of vaccine viruses in mammalian cell 
cultures [36-39].
Conclusions
No other vaccine has undergone the almost continuous 
evolution that influenza vaccines have seen. It therefore 
follows that studies which compare or elaborate the re-
sults of vaccination campaigns or trials carried out in dif-
ferent years must take into account the fact that the char-
acteristics of vaccines differ, even considerably, from one 
year to another. This evolution has surely not come to an 
end, as can be deduced from the capacity for transforma-
tion displayed by influenza viruses, the availability of 
numerous reservoirs and the continuous development of 
technologies for the preparation of vaccines. Proof of this 
can be seen in the hundreds of publications on the subject 
which appear every year in the ongoing effort to develop 
vaccines that increasingly meet the needs of recipients.
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